Skip to content
MARKETS / NASDAQ / MMED
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

MiniMed Group, Inc. MMED

3 fiscal years on record · USD · FY2025 reported · SEC filings only
$3.1B
▲ 14.3% YoY
$-333.0M
$-420.0M
In brief

What this company does

MiniMed Group, Inc. develops, manufactures and markets solutions for the management of diabetes. As of April 2026, its employee base consisted of approximately 8,000 people globally, including a technical workforce of approximately 15% in innovation and research and development. In fiscal year 2026, it generated $3.1 billion in revenue, of which approximately 82% came from sales of CGMs, other consumables, software and services. Its corporate headquarters is in Northridge, California. It operates two main manufacturing facilities, in California and Puerto Rico. MiniMed was founded by Alfred E. Mann in the early 1980s with the introduction of the MiniMed 502 insulin pump.

Written from the business description in MiniMed Group, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 29 June 2026. Every sentence was checked against that document before publication.

Growth
USD 3.1B
Revenue, FY2025 · full 3-year series below
Revenue $B Net income $B
FY2025 · Revenue 3.1 · Net income -0.3
2B202320242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−10 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -6.1% · Net -10.2%
-5%-10%202320242025
ROE
FY2025 · ROE -9.6%
-5%202320242025

Each USD of equity lost 10 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -420.0
-200M-400M202320242025

Total assetsUSD 4.6B
EquityUSD 3.6B
CashUSD 298.0M
Current ratio1.92×

Equity funds 78% of total assets.

The 3-year record
3 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 202520242023
Revenue $B3.12.72.5
Operating income $B−0.2−0.1−0.1
EBITDA $B−0.0−0.00.1
Income tax $B0.10.10.0
Net income $B−0.3−0.2−0.1
Free cash flow $B−0.4−0.1−0.1
EPS, diluted $−1.30−0.84−0.44
Dividend / sh $···
Payout %···
ROE %−9.6−6.3−3.2
Shares out B0.280.000.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 13 reconciliationsAUDITED

Reconciled in 3 of 19 fiscal years. 82 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2023

Share this section

Download image